-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87

Benzinga·10/21/2026 15:58:50
Listen to the news
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $97 to $87.